Inhibition of matrix metalloproteases by 2-(.omega.-aroylalkyl)-4-biaryl-oxobutyric acids
CA 2254750 C · Owner: Hartsough, David S. · Inventors: Hartsough, David S.; Scott, William J.; Popp, Margaret A.
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The present invention provides pharmaceutical compositions and methods for treating certain conditions comprising administering an amount of a compound or composition of the invention which is effective to inhibit the activity of at least one matrix metalloprotease, resulting in achievement of the desired effect. The compounds of the present invention are of generalized formula (I) where is 1, 2, 3 or 4 and Ar represents a substituted aromatic moiety. These compounds are useful for inhibiting matrix metalloproteases and therefore, combating conditions to which MMP's contribute such as osteoarthritis, rheumatoid arthritis septic arthritis, periodontal disease, corneal ulceration, …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed May 12, 1997 and granted September 30, 2003. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended May 12, 2017.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by May 12, 2019.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.